About 100 reports

  • 3.2 RISK FACTORS AND COMORBIDITIES
  • Risk Factors and Comorbidities for NHL

EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024 Summary Non-Hodgkin’s Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight...

  • Lymphoma
  • Japan
  • United States
  • World
  • Forecast

OUR LEAD PROJECT IS A THERAPEUTIC VACCINE FOR HIV.

  • Lymphoma
  • China
  • Celgene Corporation
  • Juno Therapeutics Inc.
  • Novartis AG

LU, XIONGBIN POLR## A Target CD## NA HIV CD## ##.

  • Lymphoma
  • North America
  • United States
  • Market Size
  • Seattle Genetics, Inc.

Disease Subarachnoid Hemorrhage GVHD Sickle Cell Disease HIV / AIDS ## ##.

  • Lymphoma
  • North America
  • United States
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Epidemiologist Insight

The literature suggests that the rise of infections, mainly HIV and AIDS that caused immunosuppression during these periods, have likely triggered the historical trend noted (Morton et al., 2006).

  • Lymphoma
  • European Union
  • Japan
  • United States
  • Roche Group
  • Risk Factors and Comorbidities for NHL

Opportunity Analyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024 Summary Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the...

  • Lymphoma
  • United States
  • GlobalData's company
  • Novartis AG
  • Roche Group
  • Epidemiologist Insight

The literature suggests that the rise of infections, mainly HIV and AIDS that caused immunosuppression during these periods, have likely triggered the historical trend noted (Morton et al., 2006).

  • Lymphoma
  • European Union
  • United States
  • Celgene Corporation
  • Roche Group

These groups could include patients receiving an organ transplant as well as HIV and AIDs patients.

  • Cancer
  • Lymphoma
  • Pathology

A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals.

  • Lymphoma
  • Japan
  • North America
  • United States
  • Forecast
  • Epidemiologist Insight

The literature suggests that the rise of infections, mainly HIV and AIDS that caused immunosuppression during these periods, have likely triggered the historical trend noted (Morton et al., 2006).

  • Lymphoma
  • European Union
  • Japan
  • North America
  • United States

A META-ANALYSIS OF THE INCIDENCE OF NON-AIDS CANCERS IN HIV-INFECTED INDIVIDUALS.

  • Lymphoma
  • Affimed Therapeutics AG
  • Incyte Corporation
  • Merck & Co., Inc.
  • Seattle Genetics, Inc.

THIS FEATURE CAN BE USED FOR THE TREATMENT OF PATHOLOGIES SUCH AS HIV/ AIDS MORE THAN ## YEARS AGO, THE TRANSCRIPTION FACTORS WERE OBTAINED FROM THE EGG PROTEIN OF XENOPUSLAEVIS.

  • Lymphoma
  • North America
  • United States
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.
  • Epithelial Ovarian Cancer
  • PIPELINE BY CHIPSCREEN BIOSCIENCES LTD, H1 2018

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H1 2018 Summary Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining...

  • Breast Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Syndax Pharmaceuticals, Inc.
  • selinexor
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017 (CONTD..1), H2 2017

Exportin ## (Chromosome Region Maintenance ## Protein Homolog or XPO##) - Overview Exportin ## (XPO##) or chromosomal maintenance ## (CRM##) is a eukaryotic protein.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Karyopharm Therapeutics Inc.
  • PIPELINE BY VIROSTATICS SRL, H1 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H1 2018 Summary According to the...

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018
  • PIPELINE BY CHIPSCREEN BIOSCIENCES LTD, H1 2018

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H1 2018 Summary Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 7 molecules. The latest report Histone Deacetylase 8 - Pipeline Review, H1...

  • Lymphoma
  • Therapy
  • China
  • Product Initiative
  • Chipscreen Biosciences Ltd
  • EWING SARCOMA
  • DIFFUSE LARGE B-CELL LYMPHOMA

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H1 2018 Summary Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface...

  • Lymphoma
  • Renal Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017 (CONTD..1), H2 2017
  • PIPELINE BY CHIPSCREEN BIOSCIENCES LTD, H2 2017

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2017 Summary According to the recently published report ’Histone Deacetylase 3 - Pipeline Review, H2 2017’; Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 14 molecules. Out of...

  • Breast Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Syndax Pharmaceuticals, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017
  • PIPELINE BY CHIPSCREEN BIOSCIENCES LTD, H2 2017

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H2 2017 Summary Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene. It is responsible for the deacetylation of lysine residues on the N-terminal...

  • Lymphoma
  • Therapy
  • China
  • Product Initiative
  • Chipscreen Biosciences Ltd
  • Target
  • Official Title

Herpesviridae Infections Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Herpesviridae Infections Global Clinical Trials Review, H2, 2017" provides an overview of Herpesviridae Infections clinical trials scenario. This report provides top line data relating to the clinical trials...

  • Cell Therapy
  • Infectious Disease
  • Lymphoma
  • World
  • GlaxoSmithKline plc

" We know from decades of work addressing the issue of HIV/ AIDS that there is no one-size-fits-all solution.

  • Digestive System Disorder
  • Lymphoma
  • Pharmaceutical
  • United States
  • Gilead Sciences, Inc.
  • HIV / AIDS
  • PRODUCTS UNDER INVESTIGATION BY UNIVERSITIES/INSTITUTES, H1 2016

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016’, provides in depth analysis on Programmed...

  • Cancer Immunotherapy
  • Lymphoma
  • Oncology
  • Therapy
  • Merck & Co., Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016
  • PIPELINE BY ALTOR BIOSCIENCE CORP, H2 2016

The preliminary results from these collaborations are very encouraging and indicate that ALT-## has substantial potency against a variety of solid tumors as well as HIV infection in experimental models.

  • Cancer
  • Interleukin
  • Lymphoma
  • Therapy
  • Altor BioScience Corporation

Fred Hutchinson Cancer Research Center (Fred Hutchinson), a subsidiary of National Comprehensive Cancer Network, is a nonprofit organization which conducts research on the prevention, diagnose and treatment of cancer, HIV/ AIDS and other life threatening diseases.

  • Lymphoma
  • Therapy
  • United States
  • Company Operations
  • Juno Therapeutics Inc.
  • Clinical Trial profile. 30 Trial Title
  • Clinical Trial profile. 49 Trial Title

AIDS - Related Cancer Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “AIDS - Related Cancer Global Clinical Trials Review, H1, 2016" provides an overview of AIDS - Related Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS - Related...

  • HIV AIDS
  • Lymphoma
  • Monoclonal Antibody
  • World
  • Product Initiative
  • ESCHERICHIA COLI INFECTIONS

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2018 Summary Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is...

  • Digestive System Disorder
  • Hospital
  • Lymphoma
  • Therapy
  • MediciNova, Inc.
  • Dedifferentiated Liposarcoma
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..2), H1 2018

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2018 Summary Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular...

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Karyopharm Therapeutics Inc.
  • Clinical Trial profile. 39 Trial Title
  • Official Title

AIDS - Related Lymphoma Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “AIDS - Related Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of AIDS - Related Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS...

  • HIV AIDS
  • Hospital
  • Lymphoma
  • World
  • Product Initiative

It provides preclinical and clinical proof to support further development of TriMix technology. eTheRNA also develops drugs for infectious diseases such as influenza, pneumonia, tuberculosis, Lyme disease, HIV and AIDS et cetera.

  • Blood Disease
  • Lymphoma
  • United States
  • World
  • MediciNova, Inc.
  • Clinical Trial profile. 143 Trial Title
  • Clinical Trial profile. 119 Trial Title

## ## ## ## ## ## Russia ## ## ## ## ## ## ## Turkey ## ## ## ## ## ## ## Brazil ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## India ## ## ## ## ## ## ## Source: GlobalData' s Pharma Intelligence Center Clin

  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • World
  • Product Initiative